Document is current
Any future updates will be listed below
-
Authors
Croizer, Hugo
Mhaidly, Rana
Kieffer, Yann https://orcid.org/0000-0003-2722-3071
Gentric, Geraldine https://orcid.org/0000-0002-7558-8705
Djerroudi, Lounes
Leclere, Renaud https://orcid.org/0000-0001-8737-6817
Pelon, Floriane
Robley, Catherine
Bohec, Mylene https://orcid.org/0000-0002-6530-596X
Meng, Arnaud
Meseure, Didier https://orcid.org/0000-0001-6730-6686
Romano, Emanuela https://orcid.org/0000-0002-1574-5545
Baulande, Sylvain https://orcid.org/0000-0003-3104-1684
Peltier, Agathe https://orcid.org/0000-0003-0017-277X
Vincent-Salomon, Anne https://orcid.org/0000-0001-5754-5771
Mechta-Grigoriou, Fatima https://orcid.org/0000-0002-3751-6989
-
Funding
Funding for this research was provided by:
Institut National Du Cancer (INCa-11692, INCa-16101)
- License Information
-
More Information
Article History
Received: 1 August 2023
Accepted: 19 March 2024
First Online: 1 April 2024
Competing interests
: F.M.-G. received research support from Innate-Pharma, Roche, Institut Roche and Bristol-Myers-Squibb (BMS). E.R. received grants from BMS, AstraZeneca, Janssen-Cilag and Fonds Amgen France; and travel support from BMS, Hoffmann La Roche, AstraZeneca, Merck Sharp & Dohme. Other authors declare no potential conflict of interest.
